{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:20Z","timestamp":1792783520552,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"ViiV Healthcare","id":[{"id":"https:\/\/ror.org\/01cc9yk21","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40121-026-01343-2","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:16:33Z","timestamp":1789139793000},"page":"3119-3134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Fostemsavir in Individuals with Multidrug-Resistant HIV-1, Stratified by Baseline Viral Load"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct02362503","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Manyu","family":"Prakash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alftan","family":"Dyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Moorhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Gilliam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"1343_CR1","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","volume":"382","author":"SG Deeks","year":"2013","unstructured":"Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382:1525\u201333.","journal-title":"Lancet"},{"key":"1343_CR2","first-page":"101","volume":"20","author":"JA Aberg","year":"2012","unstructured":"Aberg JA. Aging, inflammation, and HIV infection. Top Antivir Med. 2012;20:101\u20135.","journal-title":"Top Antivir Med"},{"key":"1343_CR3","unstructured":"UNAIDS. 2024 Global AIDS update thematic briefing note: people living with HIV. https:\/\/www.unaids.org\/en\/resources\/documents\/2024\/2024-unaids-global-aids-update-living-with-hiv. Accessed 3 Mar 2025."},{"key":"1343_CR4","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","volume":"10","author":"A Trickey","year":"2023","unstructured":"Trickey A, Sabin CA, Burkholder G, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10:e295-307.","journal-title":"Lancet HIV"},{"key":"1343_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7954","volume":"3","author":"JL Marcus","year":"2020","unstructured":"Marcus JL, Leyden WA, Alexeeff SE, et al. Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000\u20132016. JAMA Netw Open. 2020;3:e207954.","journal-title":"JAMA Netw Open"},{"key":"1343_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/QAI.0000000000002157","volume":"82","author":"R Rb-Silva","year":"2019","unstructured":"Rb-Silva R, Goios A, Kelly C, et al. Definition of immunological nonresponse to antiretroviral therapy: a systematic review. J Acquir Immune Defic Syndr. 2019;82:452\u201361.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1343_CR7","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-9-1","volume":"11","author":"S Spivack","year":"2022","unstructured":"Spivack S, Pagkalinawan S, Samuel R, Koren DE. HIV: how to manage heavily treatment-experienced patients. Drugs Context. 2022;11:2021-9-1.","journal-title":"Drugs Context"},{"key":"1343_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12879-023-08038-w","volume":"23","author":"RK Hsu","year":"2023","unstructured":"Hsu RK, Fusco JS, Henegar CE, et al. Heavily treatment-experienced people living with HIV in the OPERA\u00ae cohort: population characteristics and clinical outcomes. BMC Infect Dis. 2023;23:91.","journal-title":"BMC Infect Dis"},{"key":"1343_CR9","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1080\/21505594.2021.2004743","volume":"12","author":"C Crespo-Bermejo","year":"2021","unstructured":"Crespo-Bermejo C, de Arellano ER, Lara-Aguilar V, et al. Persistent low-level viremia in persons living with HIV undertreatment: an unresolved status. Virulence. 2021;12:2919\u201331.","journal-title":"Virulence"},{"key":"1343_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2447613","volume":"14","author":"S Zhao","year":"2025","unstructured":"Zhao S, Wang W, Li S, et al. The prevalence of low-level viraemia and its association with virological failure in people living with HIV: a systematic review and meta-analysis. Emerg Microbes Infect. 2025;14:2447613.","journal-title":"Emerg Microbes Infect"},{"key":"1343_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/03000605241301883","volume":"52","author":"MB Brizzi","year":"2024","unstructured":"Brizzi MB, Cable TL, Patel DC, Williams K, Adjei Z, Fichtenbaum CJ. Heavily treatment-experienced patients with HIV: are new mechanisms of action enough? J Int Med Res. 2024;52:3000605241301883.","journal-title":"J Int Med Res"},{"key":"1343_CR12","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1186\/s12879-017-2680-6","volume":"17","author":"V Ssempijja","year":"2017","unstructured":"Ssempijja V, Nakigozi G, Chang L, et al. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda. BMC Infect Dis. 2017;17:582.","journal-title":"BMC Infect Dis"},{"key":"1343_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003325","volume":"17","author":"A Amstutz","year":"2020","unstructured":"Amstutz A, Nsakala BL, Vanobberghen F, et al. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: an open-label randomized controlled trial in Lesotho. PLoS Med. 2020;17:e1003325.","journal-title":"PLoS Med"},{"key":"1343_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab562","volume":"8","author":"J Priest","year":"2021","unstructured":"Priest J, Hulbert E, Gilliam BL, Burton T. Characterization of heavily treatment-experienced people with HIV and impact on health care resource utilization in US commercial and Medicare Advantage health plans. Open Forum Infect Dis. 2021;8:ofab562.","journal-title":"Open Forum Infect Dis"},{"key":"1343_CR15","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s40121-023-00870-6","volume":"12","author":"JA Aberg","year":"2023","unstructured":"Aberg JA, Shepherd B, Wang M, et al. Week\u00a0240 efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1. Infect Dis Ther. 2023;12:2321\u201335.","journal-title":"Infect Dis Ther"},{"key":"1343_CR16","unstructured":"Aberg JA, Mendo Urbina F, Katlama C, et al. 7-Year sustained efficacy, safety, and immunological improvement with fostemsavir-based regimens in individuals with HIV and limited treatment options. Presented at: European AIDS Conference; October 15\u201318, 2025; Paris, France."},{"key":"1343_CR17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.chembiol.2023.03.003","volume":"30","author":"J Richard","year":"2023","unstructured":"Richard J, Pr\u00e9vost J, Bourassa C, et al. Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120. Cell Chem Biol. 2023;30:540\u201352.","journal-title":"Cell Chem Biol"},{"key":"1343_CR18","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/nchembio.2460","volume":"13","author":"M Pancera","year":"2017","unstructured":"Pancera M, Lai Y-T, Bylund T, et al. Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. Nat Chem Biol. 2017;13:1115\u201322.","journal-title":"Nat Chem Biol"},{"key":"1343_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf461","author":"M Benlarbi","year":"2025","unstructured":"Benlarbi M, Richard J, Clemente T, et al. Fostemsavir decreases the levels of anti-gp120 CD4-induced antibodies in heavily treatment-experienced people with HIV. J Infect Dis. 2025. https:\/\/doi.org\/10.1093\/infdis\/jiaf461.","journal-title":"J Infect Dis"},{"key":"1343_CR20","unstructured":"Rukobia [US prescribing information]. Durham, NC: ViiV Healthcare; 2024."},{"key":"1343_CR21","unstructured":"Rukobia [EU summary of product characteristics]. Amersfoort, Netherlands: ViiV Healthcare BV; 2025."},{"key":"1343_CR22","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/hiv.13288","volume":"23","author":"C Orkin","year":"2022","unstructured":"Orkin C, Cahn P, Castagna A, et al. Opening the door on entry inhibitors in HIV: redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV. HIV Med. 2022;23:936\u201346.","journal-title":"HIV Med"},{"key":"1343_CR23","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","volume":"382","author":"M Kozal","year":"2020","unstructured":"Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in adults with multidrug-resistant HIV-1 infection. N Engl J Med. 2020;382:1232\u201343.","journal-title":"N Engl J Med"},{"key":"1343_CR24","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.1016\/S2352-3018(20)30240-X","volume":"7","author":"M Lataillade","year":"2020","unstructured":"Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week\u00a096 results of the phase\u00a03 BRIGHTE study. Lancet HIV. 2020;7:e740\u201351.","journal-title":"Lancet HIV"},{"key":"1343_CR25","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","volume":"2","author":"C Mussini","year":"2015","unstructured":"Mussini C, Lorenzini P, Cozzi-Lepri A, et al. CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015;2:e98-106.","journal-title":"Lancet HIV"},{"key":"1343_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae469","volume":"11","author":"A Clark","year":"2024","unstructured":"Clark A, Prakash M, Chabria S, et al. Inflammatory biomarker reduction with fostemsavir over 96\u00a0weeks in heavily treatment-experienced adults with multidrug-resistant HIV-1 in the BRIGHTE study. Open Forum Infect Dis. 2024;11:ofae469.","journal-title":"Open Forum Infect Dis"},{"key":"1343_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1394644","volume":"15","author":"JM Llibre","year":"2024","unstructured":"Llibre JM, Aberg JA, Walmsley S, et al. Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5\u00a0years in the phase\u00a03 BRIGHTE study. Front Immunol. 2024;15:1394644.","journal-title":"Front Immunol"},{"key":"1343_CR28","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents With HIV. Department of Health and Human Services. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf. Accessed 13 Mar 2026."},{"key":"1343_CR29","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/infdis\/jiw263","volume":"214","author":"TB Knudsen","year":"2016","unstructured":"Knudsen TB, Ertner G, Petersen J, et al. Plasma soluble CD163 level independently predicts all-cause mortality in HIV-1-infected individuals. J Infect Dis. 2016;214:1198\u2013204.","journal-title":"J Infect Dis"},{"key":"1343_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155100","volume":"11","author":"B Grund","year":"2016","unstructured":"Grund B, Baker JV, Deeks SG, et al. Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS ONE. 2016;11:e0155100.","journal-title":"PLoS ONE"},{"key":"1343_CR31","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/infdis\/jiq118","volume":"203","author":"NG Sandler","year":"2011","unstructured":"Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203:780\u201390.","journal-title":"J Infect Dis"},{"key":"1343_CR32","doi-asserted-by":"crossref","unstructured":"Chabria S, De Wit S, Pierce A, et al. Characterization of heavily treatment-experienced HIV-1\u2013infected clinical trial participants infected with SARS-COV-2 COVID-19: fostemsavir BRIGHTE phase\u00a03 clinical trial. Presented at: IDWeek\u2122; September 29\u2013October 3, 2021; Virtual.","DOI":"10.1093\/ofid\/ofab466.1030"},{"key":"1343_CR33","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/jcph.1810","volume":"61","author":"M Magee","year":"2021","unstructured":"Magee M, Slater J, Mannino F, Ackerman P, Llamoso C, Moore K. Effect of renal and hepatic impairment on the pharmacokinetics of temsavir, the active moiety of fostemsavir. J Clin Pharmacol. 2021;61:939\u201353.","journal-title":"J Clin Pharmacol"},{"key":"1343_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/hiv.13700","volume":"26","author":"RK Hsu","year":"2025","unstructured":"Hsu RK, Brunet L, Lackey PC, et al. Immunological and virological response to fostemsavir in routine US clinical care: an OPERA cohort study. HIV Med. 2025;26:17\u201325.","journal-title":"HIV Med"},{"key":"1343_CR35","unstructured":"Ramgopal M, Henegar C, Frick AJ, et al. Characteristics and treatment outcomes of people with HIV prescribed fostemsavir in the TRIO cohort. Presented at: Conference on Retroviruses and Opportunistic Infections; March 9\u201312, 2025; San Francisco, CA."},{"issue":"3","key":"1343_CR36","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/infdis\/jiad503","volume":"229","author":"M Benlarbi","year":"2024","unstructured":"Benlarbi M, Richard J, Bourassa C, et al. Plasma human immunodeficiency virus 1 soluble glycoprotein 120 association with correlates of immune dysfunction and inflammation in antiretroviral therapy-treated individuals with undetectable viremia. J Infect Dis. 2024;229(3):763\u201374.","journal-title":"J Infect Dis"},{"issue":"3","key":"1343_CR37","first-page":"155","volume":"45","author":"V Bono","year":"2022","unstructured":"Bono V, Augello M, Tincati C, Marchetti G. Failure of CD4+ T-cell recovery upon virally-effective cART: an enduring gap in the understanding of HIV+ immunological non-responders. New Microbiol. 2022;45(3):155\u201372.","journal-title":"New Microbiol"},{"key":"1343_CR38","doi-asserted-by":"crossref","unstructured":"Dyson A, Aberg JA, Molina J-M, et al. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240\u00a0weeks of fostemsavir treatment. Presented at: IDWeek\u2122; October 11\u201315, 2023; Boston, MA.","DOI":"10.1093\/ofid\/ofad500.435"},{"key":"1343_CR39","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1177\/2047487317732432","volume":"24","author":"AB Steverson","year":"2017","unstructured":"Steverson AB, Pawlowski AE, Schneider D, et al. Clinical characteristics of HIV-infected patients with adjudicated heart failure. Eur J Prev Cardiol. 2017;24:1746\u201358.","journal-title":"Eur J Prev Cardiol"},{"key":"1343_CR40","doi-asserted-by":"publisher","first-page":"1350065","DOI":"10.3389\/fimmu.2024.1350065","volume":"15","author":"WAJW Vos","year":"2024","unstructured":"Vos WAJW, Navas A, Meeder EMG, et al. HIV immunological non-responders are characterized by extensive immunosenescence and impaired lymphocyte cytokine production capacity. Front Immunol. 2024;15:1350065.","journal-title":"Front Immunol"},{"key":"1343_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1236460","volume":"14","author":"W Zhang","year":"2023","unstructured":"Zhang W, Ruan L. Recent advances in poor HIV immune reconstitution: what will the future look like? Front Microbiol. 2023;14:1236460.","journal-title":"Front Microbiol"},{"key":"1343_CR42","unstructured":"van Doornewaard A, Jacob I, Turner M, Anderson S-J, Schroeder M. The modelled health benefits of treatment with fostemsavir in heavily treatment experienced people living with HIV. Presented at: ISPOR Europe; November 30\u2013December 3, 2021; Virtual."},{"key":"1343_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161594","volume":"11","author":"MN Hema","year":"2016","unstructured":"Hema MN, Ferry T, Dupon M, et al. Low CD4\/CD8 ratio is associated with non AIDS-defining cancers in patients on antiretroviral therapy: ANRS CO8 (Aproco\/Copilote) prospective cohort study. PLoS ONE. 2016;11:e0161594.","journal-title":"PLoS ONE"},{"key":"1343_CR44","volume":"12","author":"JM Schapiro","year":"2025","unstructured":"Schapiro JM, Kaiser R, Krystal M, et al. Fostemsavir resistance in clinical context: a narrative review. Ther Adv Infect Dis. 2025;12:20499361251325103.","journal-title":"Ther Adv Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01343-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01343-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01343-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:02:57Z","timestamp":1791954177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01343-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1343"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01343-2","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Manyu Prakash, Alftan Dyson, Fangfang Du, Bo Li, Marcia Wang, Michelle Moorhouse, Bruce Gilliam, and Bryn Jones are all employees of ViiV Healthcare or GSK and own stock in GSK.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BRIGHTE was performed in accordance with the Declaration of Helsinki. Study protocols, amendments, and other required documents were reviewed and approved by the Western Institutional Review Board (Puyallup, WA). All participants provided written informed consent before study initiation.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}